1. Campo, A, Mathai, SC, Le Pavec, J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 252–260.
Google Scholar | Crossref | Medline2. Chung, L, Farber, HW, Benza, R, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 2014; 146: 1494–1504.
Google Scholar | Crossref | Medline3. Murrell, DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 1993; 28: 78–85.
Google Scholar | Crossref | Medline4. Gabrielli, A, Svegliati, S, Moroncini, G, et al. New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol J 2012; 6: 87–95.
Google Scholar | Crossref | Medline5. Avouac, J, Borderie, D, Ekindjian, OG, et al. High DNA oxidative damage in systemic sclerosis. J Rheumatol 2010; 37: 2540–2547.
Google Scholar | Crossref | Medline6. Ogawa, F, Shimizu, K, Muroi, E, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology (Oxford) 2006; 45: 815–818.
Google Scholar | Crossref | Medline7. Volpe, A, Biasi, D, Caramaschi, P, et al. Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features. Rheumatology (Oxford) 2006; 45: 314–320.
Google Scholar | Crossref | Medline8. Stein, CM, Tanner, SB, Awad, JA, et al. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996; 39: 1146–1150.
Google Scholar | Crossref | Medline9. Seidel, P, Merfort, I, Hughes, JM, et al. Dimethylfumarate inhibits NF-B function at multiple levels to limit airway smooth muscle cell cytokine secretion. Am J Physiol Lung Cell Mol Physiol 2009; 297: L326–L339.
Google Scholar | Crossref | Medline10. Ananth, S, Babu, E, Veeranan-Karmegam, R, et al. Induction of the cystine/glutamate exchanger SLC7A11 in retinal pigment epithelial cells by the antipsoriatic drug monomethylfumarate. Invest Ophthalmol Vis Sci 2013; 54: 1592–1602.
Google Scholar | Crossref | Medline11. Conrad, M, Sato, H. The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-): cystine supplier and beyond. Amino Acids 2012; 42: 231–246.
Google Scholar | Crossref | Medline12. Tang, H, Lu, JY, Zheng, X, et al. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun 2008; 375: 562–565.
Google Scholar | Crossref | Medline13. Chen, H, Assmann, JC, Krenz, A, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J Clin Invest 2014; 124: 2188–2192.
Google Scholar | Crossref | Medline14. Singh, N, Gurav, A, Sivaprakasam, S, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 2014; 40: 128–139.
Google Scholar | Crossref | Medline15. Gold, R, Schlegel, E, Elias-Hamp, B, et al. Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE). Ther Adv Neurol Disord. Epub ahead of print 18 April 2018. DOI: 10.1177/1756286418768775.
Google Scholar | Crossref16. Yayla, ME, İlgen, U, Okatan, İE, et al. Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis. Clin Rheumatol 2020; 39: 77–83.
Google Scholar | Crossref | Medline17. Wang, YY, Yang, YX, Zhe, H, et al. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties. Drug Des Devel Ther 2014; 8: 2075–2088.
Google Scholar | Medline18. Abed, DA, Goldstein, M, Albanyan, H, et al. Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents. Acta Pharm Sin B 2015; 5: 285–299.
Google Scholar | Crossref | Medline19. Robledinos-Antón, N, Fernández-Ginés, R, Manda, G, et al. Activators and inhibitors of NRF2: a review of their potential for clinical development. Oxid Med Cell Longev 2019; 2019: 9372182.
Google Scholar | Crossref | Medline